{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"500.42","value":"900.4"},{"groupId":"OG001","spread":"398.85","value":"876.7"},{"groupId":"OG002","spread":"462.18","value":"953.6"}]}],"title":"BL Predose (n=127,110,90)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"81.65","value":"130.2"},{"groupId":"OG001","spread":"86.22","value":"145.9"},{"groupId":"OG002","spread":"75.17","value":"129.8"}]}],"title":"BL Postdose (n=118,109,85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"468.01","value":"920.2"},{"groupId":"OG001","spread":"424.72","value":"930.1"},{"groupId":"OG002","spread":"504.25","value":"991.9"}]}],"title":"Day 15 Predose (n=127,114,87)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"92.96","value":"165.4"},{"groupId":"OG001","spread":"124.38","value":"196.7"},{"groupId":"OG002","spread":"132.65","value":"196.9"}]}],"title":"Day 15 Postdose (n=121,108,89)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"456.63","value":"880.5"},{"groupId":"OG001","spread":"373.69","value":"859.7"},{"groupId":"OG002","spread":"431.93","value":"917.9"}]}],"title":"Wk 4 (n=127,111,87)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"514.94","value":"903.3"},{"groupId":"OG001","spread":"462.71","value":"949.2"},{"groupId":"OG002","spread":"458.27","value":"950.5"}]}],"title":"Wk 8 (n=126,111,90)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"436.84","value":"889.2"},{"groupId":"OG001","spread":"450.52","value":"937.8"},{"groupId":"OG002","spread":"472.95","value":"910.1"}]}],"title":"Wk 16 (n=122,112,91)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"553.17","value":"969.6"},{"groupId":"OG001","spread":"434.08","value":"918.4"},{"groupId":"OG002","spread":"418.09","value":"948.2"}]}],"title":"Wk 24 (n=113,107,85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"539.94","value":"936.6"},{"groupId":"OG001","spread":"373.17","value":"870.2"},{"groupId":"OG002","spread":"496.62","value":"967.0"}]}],"title":"Wk 28 (n=120,101,86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"515.71","value":"939.0"},{"groupId":"OG001","spread":"404.40","value":"911.6"},{"groupId":"OG002","spread":"439.04","value":"950.9"}]}],"title":"Wk 32 (n=122,107,88)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"478.40","value":"908.7"},{"groupId":"OG001","spread":"383.73","value":"901.9"},{"groupId":"OG002","spread":"422.23","value":"942.6"}]}],"title":"Wk 40 (n=118,103,84)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"477.46","value":"908.2"},{"groupId":"OG001","spread":"378.08","value":"889.8"},{"groupId":"OG002","spread":"487.98","value":"952.7"}]}],"title":"Wk 48 (n=114,103,83)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"114"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Surface expression of CD4 was assessed by FACS analysis as a marker of T helper cell count. The normal range of CD4+ T cells was defined as 404-1612 cells/µL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received rituximab, 0.5 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG000","title":"Rituximab Low Dose + Methotrexate"},{"description":"Participants received rituximab, 0.5 g, IV, on Days 1 and 15 and 1.0 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG001","title":"Rituximab Escalated Dose + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG002","title":"Rituximab High Dose + Methotrexate"}],"paramType":"MEAN","populationDescription":"SAP, n = number of participants assessed for the given parameter at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"BL, Day 15, Weeks 4, 8, 16, 24, 28, 32, 40, and 48","title":"Peripheral CD4+ T Cell Count in Cells/µL","type":"SECONDARY","unitOfMeasure":"cells/µL"}